新亞製程(002388.SZ):沈培今所持3308.33萬股司法拍賣股份完成過户
格隆匯 9 月 7日丨新亞製程(002388.SZ)公佈,公司於近日通過中國證券登記結算有限責任公司深圳分公司申請查詢獲悉,公司持股5%以上股東沈培今被司法拍賣的股份已完成過户登記手續。
此次權益變動前,沈培今持有公司3308.33萬股股份,佔公司總股本的6.57%。競買人張壽春、呂健豪未持有公司股份。
此次所拍賣股份完成股權過户手續後,沈培今將不再持有公司股份;競買人一張壽春持股數量為2380萬股,佔公司總股份比例4.72%;競買人二呂健豪持股數量為928.33萬股,佔公司總股份比例1.84%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.